Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2

FEBS Journal

Volumn 280, Issue 16, 2013, Pages 3822-3839

  Szláma, György ^a   Trexler, Mária ^a   Patthy, Lászlõ ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

latent myostatin; myostatin; promyostatin; WFIKKN1; WFIKKN2

Indexed keywords

BINDING PROTEIN; LATENT MYOSTATIN; MYOSTATIN; MYOSTATIN RECEPTOR; PROCOLLAGEN C PROTEINASE; PROMYOSTATIN; PROTEIN VARIANT; RECOMBINANT PROTEIN; TOLLOID METALLOPROTEINASE; UNCLASSIFIED DRUG; WAP KAZAL IMMUNOGLOBULIN KUNITZ AND NTR DOMAIN CONTAINING PROTEIN 1 OR GROWTH AND DIFFERENTIATION FACTOR ASSOCIATED SERUM PROTEIN 2; WAP KAZAL IMMUNOGLOBULIN KUNITZ AND NTR DOMAIN CONTAINING PROTEIN 2 OR GROWTH AND DIFFERENTIATION FACTOR ASSOCIATED SERUM PROTEIN 1; ACTIVIN RECEPTOR 2; CARRIER PROTEIN; IMMOBILIZED PROTEIN; ISOPROTEIN; MSTN PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN; PROTEIN PRECURSOR; WFIKKN1 PROTEIN, HUMAN; WFIKKNRP PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REGULATORY MECHANISM; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; GENETICS; KINETICS; LATENT MYOSTATIN; METABOLISM; PROMYOSTATIN; PROTEIN DEGRADATION; PROTEIN MICROARRAY; PROTEIN PROCESSING; REPORTER GENE; WFIKKN1; WFIKKN2;

LATENT MYOSTATIN; MYOSTATIN; PROMYOSTATIN; WFIKKN1; WFIKKN2;

ACTIVIN RECEPTORS, TYPE II; CARRIER PROTEINS; CELL LINE; GENES, REPORTER; HUMANS; IMMOBILIZED PROTEINS; KINETICS; MYOSTATIN; PEPTIDE FRAGMENTS; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; PROTEOLYSIS; RECOMBINANT PROTEINS;

EID: 84885933150     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12377     Document Type: Article

References (36)

1. McPherron AC, Lawler AM, &, Lee SJ, (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90.
2. Szabõ G, Dallmann G, Müller G, Patthy L, Soller M, &, Varga L, (1998) A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice. Mamm Genome 9, 671-672.
3. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Ménissier F, Massabanda J, et al,. (1997) A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17, 71-74.
4. Kambadur R, Sharma M, Smith TP, &, Bass JJ, (1997) Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7, 910-916.
5. McPherron AC, &, Lee SJ, (1997) Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94, 12457-12461.
6. Grobet L, Poncelet D, Royo LJ, Brouwers B, Pirottin D, Michaux C, Ménissier F, Zanotti M, Dunner S, &, Georges M, (1998) Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle. Mamm Genome 9, 210-213.
7. Roth SM, &, Walsh S, (2004) Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 7, 259-263.
8. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, &, Khurana TS, (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418-421.
9. Wagner KR, McPherron AC, Winik N, &, Lee SJ, (2002) Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52, 832-836.
10. Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, Lõpez-Soriano FJ, Han HQ, et al,. (2012) Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 3, 37-43.
11. Siriett V, Salerno MS, Berry C, Nicholas G, Bower R, Kambadur R, &, Sharma M, (2007) Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther 15, 1463-1470.
12. Matsakas A, Foster K, Otto A, Macharia R, Elashry MI, Feist S, Graham I, Foster H, Yaworsky P, Walsh F, et al,. (2009) Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 19, 489-499.
13. Li Z, Zhao B, Kim YS, Hu CY, &, Yang J, (2010) Administration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growth. Mol Reprod Dev 77, 76-82.
14. Hamrick MW, Arounleut P, Kellum E, Cain M, Immel D, &, Liang LF, (2010) Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma 69, 579-583.
15. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, &, Khurana TS, (2005) Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19, 543-549.
16. Qiao C, Li J, Jiang J, Zhu X, Wang B, Li J, &, Xiao X, (2008) Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19, 241-254.
17. Lee SJ, &, McPherron AC, (2001) Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98, 9306-9311.
18. Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, &, Wolfman NM, (2001) GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 18, 251-259.
19. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, &, Lee SJ, (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486-1488.
20. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, &, Qiu Y, (2002) The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277, 40735-40741.
21. Hill JJ, Qiu Y, Hewick RM, &, Wolfman NM, (2003) Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 17, 1144-1154.
22. Kondás K, Szláma G, Trexler M, &, Patthy L, (2008) Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11. J Biol Chem 283, 23677-23684.
23. Harrison CA, Al-Musawi SL, &, Walton KL, (2011) Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands. Growth Factors 29, 174-186.
24. Sengle G, Ono RN, Lyons KM, Bächinger HP, &, Sakai LY, (2008) A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7. J Mol Biol 381, 1025-1039.
25. Sengle G, Ono RN, Sasaki T, &, Sakai LY, (2011) Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 286, 5087-5099.
26. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, &, Springer TA, (2011) Latent TGF-β structure and activation. Nature 474, 343-349.
27. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, et al,. (2003) Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100, 15842-15846.
28. Lee SJ, (2008) Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 3, e1628.
29. Trexler M, Bányai L, &, Patthy L, (2001) A human protein containing multiple types of protease-inhibitory modules. Proc Natl Acad Sci USA 98, 3705-3709.
30. Trexler M, Bányai L, &, Patthy L, (2002) Distinct expression pattern of two related human proteins containing multiple types of protease-inhibitory modules. Biol Chem 383, 223-228.
31. Szláma G, Kondás K, Trexler M, &, Patthy L, (2010) WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity. FEBS J 277, 5040-5050.
32. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, et al,. (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 105, 4318-4322.
33. Monestier O, Brun C, Heu K, Passet B, Malhouroux M, Magnol L, Vilotte JL, &, Blanquet V, (2012) Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype. BMC Genomics 13, 541. doi: 10.1186/1471-2164-13- 541.
34. Kondás K, Szláma G, Nagy A, Trexler M, &, Patthy L, (2011) Biological functions of the WAP domain-containing multidomain proteins WFIKKN1 and WFIKKN2. Biochem Soc Trans 39, 1416-1420.
35. Mueller TD, &, Nickel J, (2012) Promiscuity and specificity in BMP receptor activation. FEBS Lett 586, 1846-1859.
36. Jiang MS, Liang LF, Wang S, Ratovitski T, Holmstrom J, Barker C, &, Stotish R, (2004) Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem Biophys Res Commun 315, 525-531.